- Home
- HWKN vs NAMS Comparison
HWKN vs NAMS Comparison
Compare HWKN & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HWKN
- NAMS
- Stock Information
- Founded
- HWKN 1938
- NAMS 2019
- Country
- HWKN United States
- NAMS Netherlands
- Employees
- HWKN N/A
- NAMS N/A
- Industry
- HWKN Specialty Chemicals
- NAMS Biotechnology: Pharmaceutical Preparations
- Sector
- HWKN Consumer Discretionary
- NAMS Health Care
- Exchange
- HWKN Nasdaq
- NAMS Nasdaq
- Market Cap
- HWKN 3.6B
- NAMS 3.1B
- IPO Year
- HWKN N/A
- NAMS N/A
- Fundamental
- Price
- HWKN $164.32
- NAMS $36.44
- Analyst Decision
- HWKN Buy
- NAMS Strong Buy
- Analyst Count
- HWKN 2
- NAMS 10
- Target Price
- HWKN $200.00
- NAMS $43.70
- AVG Volume (30 Days)
- HWKN 117.5K
- NAMS 1.4M
- Earning Date
- HWKN 10-29-2025
- NAMS 11-05-2025
- Dividend Yield
- HWKN 0.47%
- NAMS N/A
- EPS Growth
- HWKN 5.20
- NAMS N/A
- EPS
- HWKN 4.05
- NAMS N/A
- Revenue
- HWKN $1,011,824,000.00
- NAMS $64,006,000.00
- Revenue This Year
- HWKN $16.07
- NAMS N/A
- Revenue Next Year
- HWKN $6.37
- NAMS $1.67
- P/E Ratio
- HWKN $40.31
- NAMS N/A
- Revenue Growth
- HWKN 9.51
- NAMS 762.15
- 52 Week Low
- HWKN $98.30
- NAMS $14.06
- 52 Week High
- HWKN $186.15
- NAMS $41.47
- Technical
- Relative Strength Index (RSI)
- HWKN 41.90
- NAMS 62.89
- Support Level
- HWKN $158.45
- NAMS $34.36
- Resistance Level
- HWKN $176.58
- NAMS $38.13
- Average True Range (ATR)
- HWKN 6.17
- NAMS 2.55
- MACD
- HWKN -1.87
- NAMS 0.22
- Stochastic Oscillator
- HWKN 21.19
- NAMS 58.19
About HWKN Hawkins Inc.
Hawkins Inc manufactures and sells a variety of chemicals and ingredients. The firm organizes itself into three segments based on the product type. The industrial segment, which generates the majority of revenue, sells private label bleach, caustic soda, sulfuric acid, hydrochloric acid, phosphoric acid, potassium hydroxide, and aqua ammonia. The water treatment segment sells chemicals and equipment used to treat potable water, municipal and industrial wastewater, industrial process water, and non-residential swimming pool water. The health and nutrition segment sells ingredients to food, beverage, personal care, and dietary supplement producers. The majority of revenue is gained from Water Treatment.
About NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.